The national high-value medical consumables alliance procurement office has released the results of the successive procurement of coronary artery drug-eluting stent systems following the expiration of volume-based procurement (VBP) agreements. A total of 14 products from 10 manufacturers were awarded spots, according to the document, which is open for public display from November 29 to December 2, 2022.
Participation and Procurement Details
The procurement round saw participation from 3,696 medical institutions, an increase of 1,288 compared to the first VBP round. A total of 1.865 million pieces were filed for procurement. The updated rules clarified that manufacturers whose quotation prices do not exceed the highest valid filing prices will win the spots. This also allows previous non-winning bids and new products to participate if their manufacturers accept the highest valid filing prices. Additionally, the procurement cycle has been extended by one year to three years.
Winning Bids and Company Performance
The average price of the winning bids was RMB 774 (USD 108.35), or RMB 818 (USD 114.51) when including incidental service prices. MicroPort Scientific Corp. secured three spots, followed by Sino Med and JWMS with two each. Other notable companies such as Boston Scientific, Medtronic, Abbott, KinHely, Essen Technology, Lepu Medical, and Medfavour Medical each won one spot.-Fineline Info & Tech
